Alembic Pharmaceuticals Share Price Today (APLLTD)
APLLTD Today's Stock View
Alembic Pharmaceuticals closed up 0.66% at ₹823.7. With a market cap of ₹16,137.83 Cr., it trades at a P/E of 23.91. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
Alembic Pharmaceuticals Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Alembic Pharmaceuticals Limited, framed against the sector median so the premium or discount is obvious at a glance.
Alembic Pharmaceuticals Limited trades at a P/E of 23.91× and P/B of 2.84×.
Valuation
Profitability
Growth
Financial Health
Alembic Pharmaceuticals Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Alembic Pharmaceuticals Limited — derived from the live tape, not yesterday's close.
Alembic Pharmaceuticals Limited last traded at ₹823.7 with an intraday range of ₹809.5–₹834.15 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹823.70| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 884.70 | +61.00 | +7.41% |
| R3 | 860.05 | +36.35 | +4.41% |
| R2 | 847.10 | +23.40 | +2.84% |
| R1 | 835.40 | +11.70 | +1.42% |
| PIVOT | 822.45 | -1.25 | -0.15% |
| CURRENT | 823.70 | — | — |
| S1 | 810.75 | -12.95 | -1.57% |
| S2 | 797.80 | -25.90 | -3.14% |
| S3 | 786.10 | -37.60 | -4.56% |
| S4 | 761.45 | -62.25 | -7.56% |
APLLTD is trading Above CPR, indicating Bullishness
CPR is Average
Day's range: ₹809.6–₹825
Trading Inside opening range
Alembic Pharmaceuticals Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Alembic Pharmaceuticals Limited, switchable between annual and quarterly views, consolidated or standalone.
Alembic Pharmaceuticals Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹16,137.83 Cr. and reported EPS of ₹34.32.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,229 | 6,672 | 7,345 |
| Other Income | 7 | 9 | 5 | 10 | 50 | 3 | 28 | 43 | 54 |
| Total Income | 3,138 | 3,944 | 4,611 | 5,403 | 5,356 | 5,655 | 6,257 | 6,715 | 7,399 |
| Cost of Goods Sold (COGS) | 886 | 993 | 1,039 | 1,257 | 1,446 | 1,709 | 1,715 | 1,793 | 1,984 |
| Gross Profit | 2,245 | 2,942 | 3,566 | 4,136 | 3,859 | 3,944 | 4,514 | 4,879 | 5,360 |
| +Operating Expenses | 1,602 | 2,068 | 2,343 | 2,578 | 2,985 | 3,235 | 3,580 | 3,870 | 4,242 |
| EBITDA | 643 | 874 | 1,223 | 1,558 | 874 | 708 | 933 | 1,008 | 1,118 |
| +Non-Operating Expenses | 109 | 134 | 141 | 199 | 305 | 326 | 329 | 370 | 345 |
| Profit Before Tax (PBT) | 541 | 749 | 1,000 | 1,368 | 620 | 386 | 633 | 706 | 694 |
| +Tax Expense | 120 | 157 | 199 | 253 | 104 | 13 | 16 | 125 | 23 |
| Total Profit for Period | 413 | 583 | 801 | 1,147 | 521 | 342 | 616 | 582 | 671 |
| Less: Non-controlling Interests | 0 | 584 | -28 | -32 | -25 | — | — | -1 | -4 |
| Net Profit (Owner's PAT) | 413 | -1 | 829 | 1,178 | 546 | 342 | 616 | 583 | 675 |
| Earnings Per Share (EPS) | 21.89 | -0.06 | 43.97 | 59.94 | 27.76 | 17.40 | 31.33 | 29.68 | 34.33 |
| Diluted Shares Outstanding (Nos.) | 19 | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 |
| +Additional Disclosures | 3,471 | 4,768 | 4,577 | 5,289 | 6,165 | 6,961 | 7,327 | 7,820 | 8,644 |
| Sales Growth % | — | 25.68 | 17.06 | 17.10 | -1.62 | 6.54 | 10.19 | 7.12 | 10.08 |
| YoY Sales Growth % | — | 25.68 | 17.06 | 17.10 | -1.62 | 6.54 | 10.19 | 7.12 | 10.08 |
| Material Cost % | 23 | 22 | 21 | 22 | 21 | 22 | 23 | 25 | 24 |
| Employee Cost % | 20 | 19 | 20 | 19 | 21 | 21 | 23 | 23 | 24 |
| Other Cost % | 31 | 34 | 31 | 28 | 35 | 37 | 34 | 35 | 34 |
| OPM % | 21 | 22 | 27 | 29 | 16 | 13 | 15 | 15 | 15 |
| Tax % | 22 | 21 | 20 | 19 | 17 | 3 | 3 | 18 | 3 |
| Profit Growth % | — | -100.26 | 76,842.50 | 42.14 | -53.68 | -37.33 | 80.07 | -5.26 | 15.66 |
| Gross Margin % | 71.71 | 74.77 | 77.43 | 76.69 | 72.74 | 69.77 | 72.46 | 73.12 | 72.98 |
| EBITDA Margin % | 20.54 | 22.20 | 26.55 | 28.88 | 16.48 | 12.53 | 14.98 | 15.11 | 15.23 |
| Interest Coverage Ratio | 158.13 | 41.19 | 39.23 | 85.76 | 33.13 | 8.63 | 11.76 | 9.26 | 8.54 |
| Ebit | 538 | 758 | 1,066 | 1,374 | 587 | 433 | 661 | 730 | 800 |
Alembic Pharmaceuticals segment analysis: revenue and profit mix.
Disclosed business segments at Alembic Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Alembic Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Alembic Pharmaceuticals Limited.
Our AI distills the core fundamental drivers supporting Alembic Pharmaceuticals Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
Alembic Pharmaceuticals Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding at 69.74% signals management confidence and stability.
Low debt-to-equity ratio of 0.25 reflects financial prudence and resilience.
Operating margin of 10.89% indicates healthy profitability for pharma sector.
Latest quarterly EPS grew 29.2% YoY despite modest revenue expansion.
Diversified product portfolio across therapeutic areas reduces market concentration risk.
Key Risks.
P/E of 24.18 higher than forward P/E of 16.10 signals valuation concerns.
ROE of 12.36% and ROCE of 13.00% lag peer medians significantly.
FII holdings declined to 4.04%, signaling reduced foreign investor confidence.
TTM revenue growth of 4.4% lags peer median of 9.47% substantially.
High short-term debt of ₹13,740 Cr strains near-term liquidity position.
Flip Conditions.
Trim if P/E re-rates above 31. The valuation cushion thins from there.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Alembic Pharmaceuticals Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Alembic Pharmaceuticals Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
Alembic Pharmaceuticals Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Alembic Pharmaceuticals Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Alembic Pharmaceuticals Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Alembic Pharmaceuticals Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Alembic Pharmaceuticals Limited stood at 33.6% of traded volume, against a 20-day average of 43.0%.
Alembic Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings Alembic Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Alembic Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 209 documents below.
Trading Window
Alembic Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Copy of Newspaper Publication
Alembic Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Press Release
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 26, 2026, titled "Alembic Pharmaceuticals Limited…
Analysts/Institutional Investor Meet/Con. Call Updates
Alembic Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Press Release
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 19, 2026, titled "Alembic Pharmaceuticals Limited…
Investor decks & rating reports.
Alembic Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Alembic Pharmaceuticals has declared, sequenced by announce and record date.
Alembic Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Alembic Pharmaceuticals insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Alembic Pharmaceuticals as reported to SEBI — buying and selling signals from the people who know the business best.
Alembic Pharmaceuticals insider activity below tracks 11 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| NIRAYU LIMITED | Insider | 28 Mar 2025 | buy | +12.7 K | ₹1.15 Cr. | ₹905.13 |
| NIRAYU LIMITED | Insider | 21 Mar 2025 | buy | +7.6 K | ₹65.87 L | ₹866.74 |
| Chirayu Ramanbhai Amin HUF | Insider | 20 Mar 2025 | buy | +2.0 K | ₹16.69 L | ₹834.46 |
| Chirayu Ramanbhai Amin HUF | Insider | 18 Mar 2025 | buy | +1.5 K | ₹12.49 L | ₹832.52 |
| Chirayu Ramanbhai Amin HUF | Insider | 17 Mar 2025 | buy | +5.8 K | ₹48.19 L | ₹826.25 |
| Chirayu Ramanbhai Amin HUF | Insider | 27 Feb 2025 | buy | +50.0 K | ₹3.89 Cr. | ₹778.25 |
| Chirayu Ramanbhai Amin HUF | Insider | 25 Feb 2025 | buy | +7.4 K | ₹59.25 L | ₹797.91 |
| Chirayu Ramanbhai Amin HUF | Insider | 21 Feb 2025 | buy | +4.2 K | ₹34.24 L | ₹806.14 |
| Chirayu Ramanbhai Amin HUF | Insider | 20 Feb 2025 | buy | +959 | ₹7.79 L | ₹811.92 |
| Chirayu Ramanbhai Amin HUF | Insider | 14 Feb 2025 | buy | +10.0 K | ₹81.29 L | ₹812.90 |
About Alembic Pharmaceuticals Limited: business, sector, key facts.
What Alembic Pharmaceuticals Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Alembic Pharmaceuticals Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: APLLTD, BSE: 533573.
Alembic Pharmaceuticals Limited (APLLTD) is a fully integrated pharmaceutical company with a global reach. Its operations span the entire pharmaceutical value chain, from the initial research and development of new drugs to the final manufacturing, marketing, and sales of finished pharmaceutical products. This comprehensive approach allows them to exert greater control over quality and efficiency across all stages of production and distribution.
APLLTD's product portfolio is extensive and covers a wide range of therapeutic areas. This diversity is a key strength, allowing the company to cater to a broad spectrum of patient needs and market demands. Their offerings include products for cardiology, orthopaedics, diabetes management, ophthalmology, gynecology, nephrology, gastroenterology, urology, dermatology, infectious diseases, respiratory ailments (cold and cough), and even animal health. This diversification reduces reliance on any single therapeutic area and mitigates risk.
The company manufactures a variety of dosage forms, further showcasing its production capabilities. These include oral solid formulations (tablets and capsules), oncology-focused oral solids and injectables, general injectable medications, ophthalmic products, dermatological preparations, and oral suspensions. The production of active pharmaceutical ingredients (APIs) internally also grants APLLTD greater control over the supply chain and reduces dependence on external suppliers.
A significant aspect of APLLTD's business is its export operations. The company actively sells its products internationally, expanding its market reach and diversifying its revenue streams. This global presence provides resilience against fluctuations in any single national market and contributes significantly to the company's overall financial performance. The company's long history, dating back to 1907, demonstrates a sustained commitment to the pharmaceutical industry and suggests a strong foundation of experience and expertise.
In summary, Alembic Pharmaceuticals Limited operates as a comprehensive pharmaceutical company, engaged in the entire life cycle of pharmaceutical products, from research to global distribution. Its diversified product portfolio, wide range of dosage forms, and international reach contribute to its established position within the pharmaceutical market. The company's long history and vertical integration provide a solid base for continued growth and success.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Alembic Pharmaceuticals Limited (APLLTD).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Alembic Pharmaceuticals Limited (APLLTD)?
The current share price of Alembic Pharmaceuticals Limited (APLLTD) is ₹823.7. Today, the stock has gained by ₹5.40 (0.66%), trading in a range of ₹809.5 to ₹834.15. The stock opened at ₹825 with a trading volume of 1,43,213 shares.
02Is Alembic Pharmaceuticals Limited stock a good investment for long-term?
Alembic Pharmaceuticals Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹16,137.83 crores, P/E ratio of 23.91, ROE of 12.36%, and ROCE of 13.00%. The dividend yield stands at 1.34%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Alembic Pharmaceuticals Limited stock?
The 52-week high price of Alembic Pharmaceuticals Limited (APLLTD) is ₹1,044.8, while the 52-week low is ₹635.8. Currently trading at ₹823.7, the stock is 45.9% away from its 52-week low and 21.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Alembic Pharmaceuticals Limited stock at the current price?
Whether to buy Alembic Pharmaceuticals Limited stock at ₹823.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 23.91 and P/B ratio of 2.84. Today's performance shows a gain of 0.66%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Alembic Pharmaceuticals Limited and when is the next dividend?
Alembic Pharmaceuticals Limited offers a dividend yield of 1.34%, which means for every ₹100 invested at the current price of ₹823.7, you can expect to receive approximately ₹1.34 annually as dividends. The face value of the stock is ₹0.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Alembic Pharmaceuticals Limited?
Alembic Pharmaceuticals Limited's key financial metrics include: P/E Ratio: 23.91, P/B Ratio: 2.84, ROE: 12.36%, ROCE: 13.00%, Dividend Yield: 1.34%, EPS: ₹34.32, Book Value: ₹288.64, and Debt-to-Equity: 0.25. The company's market cap stands at ₹16,137.83 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Alembic Pharmaceuticals Limited stock performing today in the market?
Alembic Pharmaceuticals Limited stock opened at ₹825 and is currently trading at ₹823.7, showing a gain of ₹5.40 (0.66%). The intraday high is ₹834.15 and low is ₹809.5. The trading volume stands at 1,43,213 shares, indicating moderate market participation today.
08What is the P/E ratio of Alembic Pharmaceuticals Limited and what does it indicate?
Alembic Pharmaceuticals Limited has a Price-to-Earnings (P/E) ratio of 23.91, which means investors are willing to pay ₹23.91 for every ₹1 of earnings. With an EPS of ₹34.32, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Alembic Pharmaceuticals Limited (APLLTD) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.